Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy Leman Biotech (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2024 New trial record